Today, Jason Mast discusses the rise and fall and potential rise again of Luckin Coffee, a Chinese chain once seen as a rival to Starbucks before allegations of accounting fraud surfaced. The FDA is questioning Eli Lilly’s experimental Alzheimer’s drug, donanemab, regarding its safety and effectiveness. They are considering limiting its use to patients with a specific biomarker and assessing the risks of severe side effects. Additionally, the FDA publicly explained its rejection of Vanda Pharmaceuticals’ sleep disorder drug, requesting more evidence of effectiveness and safety. Vanda is currently facing pressure to accept a takeover bid.
Source link
FDA questions Eli Lilly’s Alzheimer’s drug, GSK to buy Elsie
